Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Xanafide

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Over-expression of P-glycoprotein (Pgp+) has been related to resistance to classical Topo II inhibitors used in the treatment of… Expand
Is this relevant?
2007
2007
Xanafide, a DNA-intercalating agent and topoisomerase II inhibitor, has previously demonstrated comparable cytotoxicity to the… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2007
2007
Secondary acute myeloid leukaemia (sAML) evolves from a prior myelodysplastic syndrome (MDS) or myeloproliferative disorder (MPD… Expand
  • table 1
  • table 2
Is this relevant?
2005
2005
2065 Background: Amonafide malate (Xanafide, Xan) is currently under study in AIPC as an individualized therapy based on the rate… Expand
Is this relevant?
2005
2005
4988 Xanafide is currently in a phase 2 trial for the treatment of hormone refractory prostate cancer (HRPC). The taxanes have… Expand
Is this relevant?
2005
2005
Proc Amer Assoc Cancer Res, Volume 46, 2005 4987 Symadex is in phase 1 for the treatment of solid tumors and shows… Expand
Is this relevant?